Emerging Antimicrobial Resistance and the Prevalence of Gram-Negative Bloodstream Infections in Pediatric Acute Myeloid Leukemia Patients Undergoing Induction Chemotherapy at Children’s Cancer Hospital Egypt 57357 - Takeaways - MDSpire

Emerging Antimicrobial Resistance and the Prevalence of Gram-Negative Bloodstream Infections in Pediatric Acute Myeloid Leukemia Patients Undergoing Induction Chemotherapy at Children’s Cancer Hospital Egypt 57357

  • By

  • Grace Mbatia

  • Reham Khedr

  • Leslie Lehmann

  • Mervat El Anany

  • Khaled Alsheshtawi

  • Omayma Hassanain

  • Sonia Ahmed

  • Omneya Hassanain

  • Lobna Shalaby

  • Alaa Elhaddad

  • April 22, 2026

  • 0 min

Share

  • 1

    The study analyzed gram-negative bloodstream infections in pediatric AML patients during induction chemotherapy at a low-middle-income country hospital.

  • 2

    Out of 90 children with GNBSI, 80% had at least one multi-drug resistant organism, highlighting significant antibiotic resistance.

  • 3

    The most common pathogens identified were E. coli (54.8%) and K. pneumoniae (16.9%), indicating prevalent gram-negative bacteria.

  • 4

    The 30-day cumulative infection-related mortality rate was 27.8%, emphasizing the severe impact of GNBSI on patient outcomes.

  • 5

    The study calls for global surveillance of antibiotic resistance and improved antibiotic stewardship to combat MDR infections.

Original Source(s)

Emerging Antimicrobial Resistance and the Prevalence of Gram-Negative Bloodstream Infections in Pediatric Acute Myeloid Leukemia Patients Undergoing Induction Chemotherapy at Children’s Cancer Hospital Egypt 57357

  • by Grace Mbatia, Reham Khedr, Leslie Lehmann, Mervat El Anany, Khaled Alsheshtawi, Omayma Hassanain, Sonia Ahmed, Omneya Hassanain, Lobna Shalaby, Alaa Elhaddad

  • April 22, 2026

Related Content

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases

Case Report: First description of an intracranial “NET” in ROHHAD syndrome; time to rename to the ROHHAD-NeCT syndrome?

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy